喹那普利相关物质A
|
|
|
- CAS号:
- 103733-49-9
- 英文名:
- QUINAPRIL RELATED COMPOUND A (50 MG) (ETHYL[3S-[2(R*),3A,11A BETA]]-1,3,4,6,11,11A-HEXAHYDRO-3-METHYL-1,4-DIOXO-ALPHA-(2-PHENY-LETHYL)-2H-PYRAZINO[1,2-B]ISOQUINOLINE-2-ACETATE)
- 英文别名:
- PD 109488;Quinapril USP RC A;Quinapril Impurity Ⅰ;Quinapril EP Impurity D;Quinapril USP impurity A;Quinapril Diketopiperazine;Quinapril Related CoMpound A;Quinapril USP Related Compound A;Ethyl (2S)-2-[(3S,11aS)-3-Methyl-1,;Quinapril Hydrochloride EP Impurity D
- 中文名:
- 喹那普利相关物质A
- 中文别名:
- 喹那普利杂质5;喹那普利杂质Ⅰ;喹那普利二酮哌嗪;喹那普利相关物质A;奎那普利EP杂质D;喹那普利EP杂质D;盐酸喹那普利杂质D;喹那普利USP RC A;喹那普利杂质D (EP);喹那普利相关化合物A(USP)
- CBNumber:
- CB9500563
- 分子式:
- C25H28N2O4
- 分子量:
- 420.5
- MOL File:
- 103733-49-9.mol
|
|
|
喹那普利相关物质A化学性质
-
沸点:
-
644.5±55.0 °C(Predicted)
-
|
-
密度:
-
1.25±0.1 g/cm3(Predicted)
-
|
-
酸度系数(pKa):
-
-1.13±0.40(Predicted)
-
|
喹那普利相关物质A性质、用途与生产工艺
盐酸喹那普利为ACEI类抗高血压药，由英国Warner-Lambert开发，1989年在英国上市，1991年经美国FDA批准上市，国内于1999年上市，由哈药集团制药总厂生产，商品名为益恒，规格为10mg每片，用于各型高血压以及充血性心力衰竭的治疗。本品为无巯基、长效、口服血管紧张素转换酶抑制剂。
盐酸喹那普利易吸潮，在受热时，结构中的仲胺极易与四氢异喹啉羧酸酰胺化形成2，5-二酮哌嗪六元环，形成喹那普利环合物杂质喹那普利相关物质A。在制备盐酸喹那普利片剂时，制粒、包衣等工序控制不严，可能会增加喹那普利相关物质A及其他杂质。
喹那普利相关物质A
上下游产品信息
上游原料
下游产品
103733-49-9, 喹那普利相关物质A 相关搜索:
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Heterocycles
- Heterocyclic Compounds
- 标准品
- 中药对照品
- 4205
- 喹那普利EP杂质D(USP杂质A)
- 喹那普利杂质Ⅰ
- 盐酸喹那普利杂质D
- 喹那普利EP杂质D
- 盐酸喹那普利杂质Ⅰ [3S-[2(R* ),3Α,11ΑΒ]]-1,3,4,6,11,11Α-六氢-3-甲基-1,4-二氧代-Α-(2-苯乙基)-2H-吡嗪并[1,2-B]异喹啉-2-乙酸乙酯
- 奎那普利EP杂质D
- 喹那普利相关物质A USP标准品
- 乙基(2S)-2-[(3S,11AS)-3-METHYL-1,4-DIOXO-1,3,4,6,11,11A-HEXAHYDRO-2H-PYRAZINO[1,2-B]ISOQUINOLIN-2-YL]-4-PHENYLBUTANOATE 标准品
- 喹那普利杂质5
- 喹那普利相关化合物A(USP)
- 喹那普利杂质D (EP)
- 盐酸喹那普利杂质Ⅰ [3S-[2(R* ),3Α,11ΑΒ]]-1,3,4,6,11,11Α-六氢-3-甲基-1,4-二氧代-Α-(2-苯乙基)-2H-吡嗪并[1,2-B]异喹啉-2-乙酸乙酯
- 盐酸喹那普利杂质Ⅰ [3S-[2（R* ），3α，11αβ]]-1，3，4，6，11，11α-六氢-3-甲基-1，4-二氧代-α-（2-苯乙基）-2H-吡嗪并[1，2-b]异喹啉-2-乙酸乙酯
- 喹那普利相关物质A
- 喹那普利二酮哌嗪
- 喹那普利USP RC A
- 103733-49-9
- Quinapril EP Impurity D (Quinapril USP Related Compound A)
- Quinapril Related Compound A (50 mg) (Ethyl [3S-[(2R*), 3a, 11ab]]-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-a-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetate)
- Quinapril Hydrochloride EP Impurity D
- ethyl (2S)-2-[(3S,11aS)-3-methyl-1,4-dioxo-1,3,4,6,11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinolin-2-yl]-4-phenylbutanoate
- Quinapril USP Related Compound A
- Quinapril Impurity Ⅰ Ethyl[3S-[2(R*),3a,11a
β]]-1,3,4,6,11,11a-hexahydro- 3-methyl-1,4-dioxo-α
-(2-phenylethyl)-2H-pyrazino[1
,2-b]isoquinoline-2-acetate
- Quinapril Related Compound A (Ethyl[3S-[2(R*),3a,11a beta]]-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-d (1593412)
- Quinapril Hydrochloride Impurity Ⅰ：Quinapril Diketopiperazine
- (αS,3S,11aS)-1,3,4,6,11,11a-Hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetic Acid
- Quinapril Related Compound A(Secondary Standards traceble to USP)
- Quinapril EP Impurity D/ Quinapril Related Compound A (Quinapril Diketopiperazine)
- 2H-Pyrazino[1,2-b]isoquinoline-2-acetic acid, 1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)-, ethyl ester, (αS,3S,11aS)-
- Ethyl (2S)-2-[(3S,11aS)-3-Methyl-1,
- Quinapril USP impurity A
- Quinapril Impurity Ⅰ
- Ethyl [3S-[2(R*),3a,11a beta]]-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-alpha-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetate
- Quinapril Hydrochloride Impurity Ⅰ：Quinapril Diketopiperazine
- Quinapril Impurity 4（Quinapril EP Impurity D）
- Quinapril EP Impurity D
- Quinapril USP RC A
- (αS,3S,11aS)-1,3,4,6,11,11a-Hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetic acid ethyl ester
- (alphaS,3S,11aS)-1,3,4,6,11,11a-Hexahydro-3-methyl-1,4-dioxo-alpha-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetic acid ethyl ester
- Quinapril Related CoMpound A
- (αS,3S,11aS)-1,3,4,6,11,11a-Hexahydro-3-Methyl-1,4-dioxo-α-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetic Acid
- QUINAPRIL RELATED COMPOUND A (50 MG) (ETHYL[3S-[2(R*),3A,11A BETA]]-1,3,4,6,11,11A-HEXAHYDRO-3-METHYL-1,4-DIOXO-ALPHA-(2-PHENY-LETHYL)-2H-PYRAZINO[1,2-B]ISOQUINOLINE-2-ACETATE)
- 2H-Pyrazino(1,2-B)isoquinoline-2-acetic acid, 1,3,4,6,11,11A-hexahydro-3-methyl-1,4-dioxo-alpha-(2-phenylethyl)-, ethyl ester, (3S-(2(R*),3alpha-11abeta))-
- (aS,3S,11aS)-1,3,4,6,11,11a-Hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)-2H-pyrazino[1,2-β]isoquinoline-2-acetic Acid
- Quinapril Diketopiperazine
- PD 109488
- (aS,3S,11aS)-1,3,4,6,11,11a-Hexahydro-3-methyl-1,4-dioxo-a-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetic Acid
- QUINAPRIL RELATED COMPOUND A (50 MG) (ETHYL[3S-[2(R*),3A,11A BETA]]-1,3,4,6,11,11A-HEXAHYDRO-3-METHYL-1,4-DIOXO-ALPHA-(2-PHENY-LETHYL)-2H-PYRAZINO[1,2-B]ISOQUINOLINE-2-ACETATE)